7 results on '"subgroup analysis"'
Search Results
2. Querschnittsanalyse zur Routinebehandlung von Prostatakrebspatienten.
- Author
-
Schulze, M., Stiegler, H., Thielecke, C., Colling, C., and Merseburger, A.S.
- Abstract
Copyright of Der Urologe A is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2014
- Full Text
- View/download PDF
3. 106. Kriterien zur Biostatistik bei der Chirurgie des Magencarcinoms.
- Author
-
Bauer, P., Stützer, H., and Vierzig, A.
- Abstract
Copyright of Langenbecks Archiv fuer Chirurgie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 1987
- Full Text
- View/download PDF
4. [GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence].
- Author
-
Ebenberger A, Nussbaumer-Streit B, Teufer B, Langer G, Schwingshackl L, Töws I, and Gartlehner G
- Subjects
- Consensus, Germany, Humans, Process Assessment, Health Care, Health Equity
- Abstract
Objectives: The aim of this paper is to describe a conceptual framework for how to consider health equity in the Grading Recommendations Assessment and Development Evidence (GRADE) guideline development process., Study Design and Setting: Consensus-based guidance developed by the GRADE working group members and other methodologists. This is a German translation of the original paper published in English., Results: We developed consensus-based guidance to help address health equity when rating the certainty of synthesized evidence (i.e., quality of evidence). When health inequity is determined to be a concern by stakeholders, we propose five methods for explicitly assessing health equity: (1) include health equity as an outcome; (2) consider patient-important outcomes relevant to health equity; (3) assess differences in the relative effect size of the treatment; (4) assess differences in baseline risk and the differing impacts on absolute effects; and (5) assess indirectness of evidence to disadvantaged populations and/or settings., Conclusion: The most important priority for research on health inequity and guidelines is to identify and document examples where health equity has been considered explicitly in guidelines. Although there is a weak scientific evidence base for assessing health equity, this should not discourage the explicit consideration of how guidelines and recommendations affect the most vulnerable members of society., (Copyright © 2020. Published by Elsevier GmbH.)
- Published
- 2020
- Full Text
- View/download PDF
5. Adjuvante Therapie des Kolonkarzinoms
- Author
-
Hans-Peter Bruch, Dirk Arnold, Anke Reinacher-Schick, Hans-Joachim Schmoll, Karsten Ridwelski, Thomas Kirchner, Tanja Trarbach, and Stefan Kubicka
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Predictive marker ,Colorectal cancer ,business.industry ,Medizin ,Combination chemotherapy ,Subgroup analysis ,Hematology ,General Medicine ,medicine.disease ,Oxaliplatin ,Capecitabine ,Internal medicine ,medicine ,Adjuvant therapy ,Combined Modality Therapy ,business ,medicine.drug - Abstract
The goal of improving adjuvant treatment can be reached in two ways: firstly, by developing more effective drugs and protocols and, secondly, by selecting suitable patients on the basis of clinical and molecular factors. In UICC (Union internationale contre le cancer) stage II, microsatellite instability (MSI) is a strong prognostic factor. Whether it can also be used as a predictive marker is currently a matter of controversy because the available data are contradictory. The question whether or not the MSI status should be checked before treatment decisions are made in stage II patients can therefore not be clearly answered at present. For adjuvant treatment in stage III, with capecitabine/oxaliplatin (XELOX) there is now a new protocol available that is based on the orally administered prodrug capecitabine. With regard to the question of how much older patients in this stage may also benefit from a combination chemotherapy, new--and contradictory--data have emerged recently: firstly, preliminary results of two new studies have given rise to safety concerns and, secondly, an analysis by the 'ACCENT Collaborative Group' indicated lower efficacy of the 'newer' adjuvant protocols in older people. These findings, however, have now been called into question as a result of a new subgroup analysis from the XELOXA study. The expert group therefore recommended that the decision whether to treat patients older than 70 years with an (oral) fluoropyrimidine alone or in combination with oxaliplatin should be based on clinical parameters such as biological age and comorbidities.
- Published
- 2010
6. Prognostische Relevanz von p21, p53 und deren Bedeutung als Response-Parameter für die adjuvante Therapie des kolorektalen Karzinoms
- Author
-
Sybille Lipka, Heinz-Johannes Buhr, Martin Kruschewski, K. Müller, and Aurelia Noske
- Subjects
medicine.medical_specialty ,Colorectal cancer ,business.industry ,Subgroup analysis ,medicine.disease ,Gastroenterology ,Log-rank test ,ddc: 610 ,Internal medicine ,Cohort ,medicine ,Adjuvant therapy ,Stage (cooking) ,business ,Survival rate ,Survival analysis - Abstract
Background: The role of p53 and p21 as prognostic factors and response-parameters for adjuvant therapy in colorectal carcinomas are still under controversial debate. We aimed to evaluate the importance of both genes in a prospectively documented patient cohort. Patients and methods: Collection of follow-up data of 125 patients with sporadic colorectal carcinoma (stage UICC II/III), who underwent curative resection between 1995 and 2001. The median follow-up time was 51,8 ± 2,5 months. We investigated the protein expression of p53 and p21 in tumour tissues by immunohistochemistry. The probability of overall survival as a function of time was determined by the Kaplan-Meier method. Differences in survival curves were compared by the log rank test. Results: Patients had a 5-year overall survival rate of 64 % and a progression-free survival rate of 62 %. We observed an expression of p53 in 63 % and of p21 in 26 % of the carcinomas. In univariate survival analysis, p53 expression was associated with a significant better overall survival (p = 0,048). Negative p21 expression was significantly related to a better progression-free (82,4 ± 4,8 months; p = 0,02) and overall survival (83,9 ± 4,5 months; p = 0,005). In a subgroup analysis, we found a significant survival advantage for patients with p21-negative/p53-positive carcinomas. The progression-free survival was 86,5 ± 5,9 months (p = 0,007) and the overall survival 94,5 ± 5,0 months (p < 0,0001) as compared to other subgroups p21−/p53−, p21+/p53+, p21+/p53−. Adjuvant therapy revealed a benefit in overall survival in patients with p21-negative carcinomas as compared to patients without therapy (90,7 ± 4,7 vs. 58,3 ± 6,1 months, p = 0,017). Patients with p21-negative/p53-positive carcinomas had a favourable overall survival after adjuvant therapy (99,4 ± 4,8 vs. 66,9 ± 6,8 months, p = 0,012). Conclusion: The cell cycle regulator p21 has prognostic impact on patient survival as well as effects on adjuvant therapy. Moreover, the combination of p21−/p53+ expression in colorectal carcinomas might be particularly important.
- Published
- 2008
7. [Types of pain coping in chronic pain patients].
- Author
-
Grolimund J, Studer M, Stewart JA, Egloff N, and Grosse Holtforth M
- Subjects
- Adaptation, Psychological, Depression, Humans, Pain Management, Pain Measurement, Chronic Pain
- Abstract
Background: The characterization of subtypes of chronic pain patients based on their pain coping profiles may contribute to a better understanding of the pain syndrome, to more specific indications of established treatment options as well as to further development of therapeutic interventions., Objective: The aim of this study was to examine whether different subgroups of chronic pain patients emerge when using the German pain coping questionnaire (FESV) to identify homogeneous subgroups of pain coping patterns. Furthermore, the aim was to examine whether these pain coping subgroups differ in terms of sociodemographic characteristics, as well as pain and treatment-related aspects., Material and Methods: A total of 166 inpatients with a chronic pain disorder according to ICD-10 F45.41 were examined as part of the routine assessment within an interdisciplinary pain treatment program. Cognitive and behavioral pain coping and pain-related psychological impairment were measured with the FESV as components of pain coping. Using cluster analyses, homogeneous patient subgroups were generated on the basis of pain coping data. The resulting subgroups were subsequently compared regarding sociodemographic characteristics, pain-related impairment, global psychological distress, depression, anxiety, perceived stress, utilization of social support and motivation for psychotherapy., Results and Conclusion: The results revealed three distinct subgroups regarding pain coping patterns: (1) high impairment and high coping, (2) low impairment and high coping and (3) high impairment and low coping. The subgroups differed significantly in almost all characteristics, except for pain duration and pain intensity. The categorization into the abovementioned pain coping subtypes may assist clinicians in tailoring pain treatment to the needs and characteristics of the individual patients.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.